GR3019229T3 - Use of protective agents against reactive oxygen species - Google Patents
Use of protective agents against reactive oxygen speciesInfo
- Publication number
- GR3019229T3 GR3019229T3 GR960400637T GR960400637T GR3019229T3 GR 3019229 T3 GR3019229 T3 GR 3019229T3 GR 960400637 T GR960400637 T GR 960400637T GR 960400637 T GR960400637 T GR 960400637T GR 3019229 T3 GR3019229 T3 GR 3019229T3
- Authority
- GR
- Greece
- Prior art keywords
- oxygen species
- reactive oxygen
- protective agents
- agents against
- against reactive
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH] (Somatotropin)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/204—IL-6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Virology (AREA)
- AIDS & HIV (AREA)
- Transplantation (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Psychology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US60285090A | 1990-10-25 | 1990-10-25 | |
PCT/US1991/007759 WO1992007578A1 (en) | 1990-10-25 | 1991-10-21 | Use of protective agents against reactive oxygen species |
Publications (1)
Publication Number | Publication Date |
---|---|
GR3019229T3 true GR3019229T3 (en) | 1996-06-30 |
Family
ID=24413043
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GR960400637T GR3019229T3 (en) | 1990-10-25 | 1996-03-06 | Use of protective agents against reactive oxygen species |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP0554381B2 (el) |
JP (2) | JPH06503320A (el) |
AT (1) | ATE133073T1 (el) |
CA (1) | CA2092718C (el) |
DE (1) | DE69116565T2 (el) |
DK (1) | DK0554381T3 (el) |
ES (1) | ES2084190T3 (el) |
GR (1) | GR3019229T3 (el) |
WO (1) | WO1992007578A1 (el) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5560908A (en) * | 1993-01-22 | 1996-10-01 | Kanegafuchi Kagaku Kogyo Kabushiki Kaisha | Therapeutic agent for NIDDM |
US5935924A (en) * | 1994-04-15 | 1999-08-10 | Genentech, Inc. | Treatment of congestive heart failure |
US5661122A (en) * | 1994-04-15 | 1997-08-26 | Genentech, Inc. | Treatment of congestive heart failure |
US5610134A (en) * | 1994-04-15 | 1997-03-11 | Genentech, Inc. | Treatment of congestive heart failure |
AUPO263696A0 (en) * | 1996-09-27 | 1996-10-24 | Walter And Eliza Hall Institute Of Medical Research, The | A process for culturing cells |
SE9703929D0 (sv) * | 1996-11-22 | 1997-10-28 | Pharmacia & Upjohn Ab | Therapeutical use and method |
EP1043027A1 (en) * | 1999-04-08 | 2000-10-11 | Applied Research Systems ARS Holding N.V. | Treatment of multiple sclerosis with a combination of Interferon and Growth hormone |
DE60316407T2 (de) * | 2002-02-06 | 2008-06-19 | Ares Trading S.A. | Tumornekrosefaktor in kombination mit interferon zur behandlung und/oder verhinderung einer demyelinisierenden krankheit |
WO2004014412A1 (ja) * | 2002-08-09 | 2004-02-19 | Kaken Pharmaceutical Co., Ltd. | 心筋細胞保護剤 |
EP1572291B1 (en) * | 2002-10-08 | 2013-04-03 | Ares Trading S.A. | The use of cytokine able to bind il-18bp and of inhibiting the activity of a second cytokine |
US7476653B2 (en) | 2003-06-18 | 2009-01-13 | Tranzyme Pharma, Inc. | Macrocyclic modulators of the ghrelin receptor |
CU23558A1 (es) | 2006-02-28 | 2010-07-20 | Ct Ingenieria Genetica Biotech | Compuestos análogos a los secretagogos peptidicos de la hormona de crecimiento |
MX2009008574A (es) | 2007-02-09 | 2009-12-09 | Tranzyme Pharma Inc | Moduladores del receptor de grelina macrociclicos y metodos para usar el mismo. |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ219027A (en) * | 1986-01-24 | 1989-09-27 | Genentech Inc | Antiviral composition containing interferon tumour necrosis factor and/or lymphotoxin |
US5057494A (en) * | 1988-08-03 | 1991-10-15 | Ethicon, Inc. | Method for preventing tissue damage after an ischemic episode |
IL97779A (en) * | 1990-04-10 | 2000-01-31 | Genentech Inc | Compositions for cytoprotection against radiation and chemotherapy injury or risk thereof |
-
1991
- 1991-10-21 EP EP91920537A patent/EP0554381B2/en not_active Expired - Lifetime
- 1991-10-21 JP JP4500764A patent/JPH06503320A/ja active Pending
- 1991-10-21 DK DK91920537.7T patent/DK0554381T3/da active
- 1991-10-21 DE DE69116565T patent/DE69116565T2/de not_active Expired - Fee Related
- 1991-10-21 WO PCT/US1991/007759 patent/WO1992007578A1/en active IP Right Grant
- 1991-10-21 CA CA002092718A patent/CA2092718C/en not_active Expired - Lifetime
- 1991-10-21 ES ES91920537T patent/ES2084190T3/es not_active Expired - Lifetime
- 1991-10-21 AT AT91920537T patent/ATE133073T1/de active
-
1996
- 1996-03-06 GR GR960400637T patent/GR3019229T3/el unknown
-
2001
- 2001-11-21 JP JP2001356092A patent/JP2002179590A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
WO1992007578A1 (en) | 1992-05-14 |
JP2002179590A (ja) | 2002-06-26 |
EP0554381A1 (en) | 1993-08-11 |
ES2084190T3 (es) | 1996-05-01 |
DE69116565T2 (de) | 1996-08-01 |
DE69116565D1 (de) | 1996-02-29 |
ATE133073T1 (de) | 1996-02-15 |
EP0554381B2 (en) | 2000-04-26 |
CA2092718A1 (en) | 1992-04-26 |
JPH06503320A (ja) | 1994-04-14 |
AU661463B2 (en) | 1995-07-27 |
CA2092718C (en) | 2007-08-07 |
AU8941291A (en) | 1992-05-26 |
EP0554381B1 (en) | 1996-01-17 |
DK0554381T3 (da) | 1996-04-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GR3019229T3 (en) | Use of protective agents against reactive oxygen species | |
Redmond et al. | Surgical anatomy of the human spleen | |
EP0673234A4 (en) | TISSUE PROTECTION AND RECEIVING BLENDS. | |
LTIP1705A (en) | Method for protection of cultured plant, method for combating with pests and microbicidal material | |
SE7806939L (sv) | Retentionspreparat for tandproteser | |
CA2265547A1 (en) | Method of treating endothelial injury | |
GEP20033079B (en) | Pharmaceutical Compositions for Treatment of Diseases Caused by Estrogens Deficiency | |
Oosterhof et al. | In vivo effects of high energy shock waves on urological tumors: an evaluation of treatment modalities | |
NZ308391A (en) | Use of 1,2,4-triazole derivatives for the manufacture of a medicament for the treatment of cancers | |
GR3031129T3 (en) | Enhancement of glutathione levels with glutamine | |
MY102648A (en) | Pharmacological / cosmetic preparation | |
DE59600683D1 (de) | Verwendung von Trospiumchlorid zur Herstellung eines Arzneimittels zur Behandlung von Blasenkrankheiten | |
AU3324100A (en) | Use of pirenoxine for the protection of corneal tissues in photokeratectomy | |
Lamke | The influence of different “skin grafts” on the evaporative water loss from burns | |
CA2078544A1 (en) | Method and compositions for treating injury | |
UY26514A1 (es) | " composición para el tratamiento de tejidos danados". | |
MILLER et al. | HEALING OF SECOND DEGREE BURNS: Comparison of Effects of Early Application of Horaografts and Coverage with Tape | |
Stanley et al. | Whitehead's varnish and Jelonet--a better dressing for skin graft donor sites than Jelonet alone. | |
Juchelková et al. | Radioprotective Effects of Flurbiprofen and Its | |
EA200000762A1 (ru) | Способ для консервации органов или других тканей для трансплантации | |
OHKOSHI | Effect of aprotinin on growth of 3-methylcholanthrene-induced squamous cell carcinoma in mice | |
EP0169895A1 (en) | PLANT MEDICINAL COMPOSITIONS FOR THE TREATMENT OF SOME HEPATIC AND BILIARY CONDITIONS. | |
Rice et al. | The role of triglyceride accumulation and of necrosis in the hemodynamic responses of the isolated perfused rat liver after administration of carbon tetrachloride | |
CA2097878A1 (en) | Therapeutic agent for neutropenia | |
HU9301719D0 (en) | Medical preparatives for treatment of b-cell tumours |